WHO decides to restart Covid drug trial

WHO( World Health Organization) has decided to restart the Covid drug trial with main focus on immune system. It is going to be an international clinical trial of three existing drugs, which can save the life of many hospitalised covid-19 patients.

On 18 March, Tedros Adhanom Ghebreyesus, WHO director general announced about the clinical trial called as Solidarity for the first time. The trial would be done on three existing drugs that dampen inflammation — Infliximab, Imatinib and Artesunate.


The first drug Infliximab is used to treat autoimmune conditions, including Crohn’s disease and rheumatoid arthritis. The second one is Imatinib, it is a drug used to treat cancer.

The researchers believes that Infliximab can also be the cure of Coronavirus and inflammation. The last drug for trail is Artesunate, it is used to cure malaria, reports says that it has some anti-inflammatory effects.


Sources says that by October, more than 11,000 participants had enrolled who are hospitalised with Covid-19. It is said that the participants belongs from 30 different countries.

Also read: SpaceX launches ‘DOGE-1 Mission to the Moon’ next year

About the author

Add Comment

Click here to post a comment